UPDATE 1-Enzon Pharmaceuticals posts narrower Q2 net loss

(Recasts; adds details)

July 24 (Reuters) - Enzon Pharmaceuticals Inc (ENZN.O) reported a slightly narrower quarterly net loss helped by higher revenue growth across all business segments.

Net loss for the second quarter ended June 30 was $1.7 million, or 4 cents per share, compared with $2.0 million, or 4 cents per share, a year earlier. Excluding items, it posted a loss of 1 cent a share.

Total revenue rose about 4 percent to $51.0 million.

Analysts were expecting the company to post a loss of 22 cents a share, on revenue of $44.5 million, according to Reuters Estimates.

The Bridgewater, New Jersey-based company, which was advised by billionaire investor Carl Icahn to review strategic transactions, announced the spin-off of its biotechnology business in May.

The spin-off, which will result in two independent public companies, is expected to be completed in the fourth quarter of 2008.

Shares of the company closed at $8.29 Tuesday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Bernard Orr)